I would be very careful to maintain a short position on this one. having crossed the yearly target an upgrade is looming and short positions could be burnt bad. There are very few small biotechs making profits and is not dependent on any approval / marketing issues. Rise from 11 to 14 is very much justified. They have already raised their annual revenue estimates so what are you concerned about??? 2014 this one is set to go much higher.